Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin vs Ticarcillin/Clavulanate in cSSSI
NCT00249197Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 1997
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of levofloxacin in Complicated skin and skin structure infection (cSSSI) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Clinical response rate. Started Jan 1997; status: completed.
02
Drugs
levofloxacin
03
Conditions
Complicated skin and skin structure infection (cSSSI)
Beyond the preview
Go deeper on NCT00249197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249197.